Phase II/III Study of S-877503 in Pediatric Patients with Attention-deficit/Hyperactivity Disorder

SHIONOGI & CO., LTD.0 个研究点开始时间: 2013年5月8日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Patient aged 6 years or older to less than 18 years at the time of signing the informed
•consent form.
•2) Patient meets the DSM-IV-TR criteria for a primary diagnosis of ADHD (predominantly
•inattentive type [314.00], predominantly hyperactive-impulsive type [314.01],
•and combined type [314.01]). And et al.

•1) Patient has complications such as serious hepatic disorder, renal disorder, heart disease,
•lung disease, hematological disease, and metabolic disease.
•2) Patient has psychiatric disease such as schizophrenia, bipolar disorder, and pervasive
•developmental disorder.
•3) Patient has personality disorder or mental retardation.
•4) Patient is orthostatic hypotensive or hypertensive.
•5) Patient had a documented allergy, hypersensitivity or intolerance to guanfacine
•hydrocholoride.
•6) Patient considered a suicide risk. And et al.

发起方